All In Biotech

Drug Trial Radar · NCT07048262

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 3, 2025

Primary completion

May 6, 2029

Study completion Jun 6, 2029

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (human normal immunoglobulin G \[IgG\] inhalation solution) compared with placebo over 52 weeks. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the time to first (TTF) exacerbation.

Conditions

  • Non-cystic Fibrosis Bronchiectasis

Interventions

  • CSL787Biological

    CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of 52 weeks.

  • PlaceboDrug

    Participants will receive a matching volume of placebo QD over a period of 52 weeks.

  • NebulizerDevice

    The nebulizer is a CE-marked device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first (TTF) ExacerbationTime frame: Up to Week 52

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • The Prince Charles Hospital

    Queensland, Australia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Fukuoka University Chikushi Hopsital

    Chikushino-shi, Japan · Recruiting

  • Kyusho Central Hospital of the Mutual Aid Association of Public School Teachers

    Fukuoka, Japan · Recruiting

  • Ibaraki Prefectural Central Hospital

    Ibaraki, Japan · Recruiting

  • Kazunori Tobino Iizuka Hospital

    Iizuka-shi, Japan · Recruiting

  • National Hospital Organization Minami Kyoto Hospital

    Kyoto, Japan · Recruiting

  • Matsusaka Municipal Hospital

    Mie, Japan · Recruiting

  • National Hospital Organization Kinki Chuo Chest Medical Center

    Osaka, Japan · Recruiting

  • Shimonoseki City Hospital

    Shimonoseki-shi, Japan · Recruiting

  • Japan Anti-Tuberculosis Association, Fukujuji Hospital

    Tokyo, Japan · Recruiting

  • Keio University Hospital

    Tokyo, Japan · Recruiting

  • National Hospital Organization Mie Chuo Medical Center

    Tsu, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.